WO1996026718A3 - Controlled release tablet - Google Patents

Controlled release tablet Download PDF

Info

Publication number
WO1996026718A3
WO1996026718A3 PCT/US1996/002290 US9602290W WO9626718A3 WO 1996026718 A3 WO1996026718 A3 WO 1996026718A3 US 9602290 W US9602290 W US 9602290W WO 9626718 A3 WO9626718 A3 WO 9626718A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
controlled release
pharmaceutical agent
excipient
release tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/002290
Other languages
French (fr)
Other versions
WO1996026718A2 (en
Inventor
Cherng-Ju Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Priority to AT96908487T priority Critical patent/ATE228829T1/en
Priority to DE69625189T priority patent/DE69625189D1/en
Priority to JP8526317A priority patent/JPH11509169A/en
Priority to AU51711/96A priority patent/AU722741B2/en
Priority to EP96908487A priority patent/EP0821582B1/en
Publication of WO1996026718A2 publication Critical patent/WO1996026718A2/en
Publication of WO1996026718A3 publication Critical patent/WO1996026718A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

A controlled release tablet including a pharmaceutical agent and an excipient. The excipient includes at least about 50 % of a water swellable polymer and a lubricant. The water swellable polymer is chosen such that the swelling rate of the polymer is equal to the dissolution rate of the swollen polymer. The excipient may also include such other ingredients as diluents, fillers, binders and other pharmacologically inactive compounds. The polymer is chosen with the pharmaceutical agent in mind such that the tablet will be fully dissolved at the same time that the last of the pharmaceutical agent is released.
PCT/US1996/002290 1995-02-28 1996-02-28 Controlled release tablet Ceased WO1996026718A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT96908487T ATE228829T1 (en) 1995-02-28 1996-02-28 CONTROLLED-RELEASE TABLET
DE69625189T DE69625189D1 (en) 1995-02-28 1996-02-28 CONTROLLED RELEASE TABLET
JP8526317A JPH11509169A (en) 1995-02-28 1996-02-28 Controlled release tablets
AU51711/96A AU722741B2 (en) 1995-02-28 1996-02-28 Controlled release tablet
EP96908487A EP0821582B1 (en) 1995-02-28 1996-02-28 Controlled release tablet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39579295A 1995-02-28 1995-02-28
US08/395,792 1995-02-28

Publications (2)

Publication Number Publication Date
WO1996026718A2 WO1996026718A2 (en) 1996-09-06
WO1996026718A3 true WO1996026718A3 (en) 1996-10-10

Family

ID=23564527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002290 Ceased WO1996026718A2 (en) 1995-02-28 1996-02-28 Controlled release tablet

Country Status (11)

Country Link
EP (1) EP0821582B1 (en)
JP (1) JPH11509169A (en)
AR (1) AR003928A1 (en)
AT (1) ATE228829T1 (en)
AU (1) AU722741B2 (en)
CA (1) CA2213455A1 (en)
DE (1) DE69625189D1 (en)
MY (1) MY113429A (en)
PA (1) PA8388101A1 (en)
TW (1) TW431891B (en)
WO (1) WO1996026718A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
CA2275604A1 (en) * 1997-01-03 1998-07-09 Kenneth Iain Cumming Sustained release cisapride mini-tablet formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
PT1251832E (en) 2000-02-04 2007-01-31 Depomed Inc Shell-and-core dosage form approaching zero-order drug release
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
BRPI0406749A (en) 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Methods related to treatment of bowel dysfunction and pharmaceutical composition
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP2008503475A (en) 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド Formulation with modified release of memantine
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH LOW ESCITALOPRAM AND BUPROPION DOSE COMBINATION
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
WO2010026467A2 (en) 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CA2758976C (en) 2009-04-20 2015-02-03 Alain Baron Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2630491A4 (en) 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
PT2661266T (en) 2011-01-07 2020-11-30 Anji Pharma Us Llc Chemosensory receptor ligand-based therapies
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
JP2016520653A (en) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド Acamprosate formulation, method of using the same, and combination containing the same
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
IL274701B2 (en) 2017-12-01 2024-07-01 Ultragenyx Pharmaceutical Inc Creatine prodrugs, compositions and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.J.KIM: "DRUG RELEASE FROM COMPRESSED HYDROPHILIC POLYOX-WSR TABLETS", ADVANCE ACS ABSTRACTS, vol. 3, no. 3, 1 February 1995 (1995-02-01), XP002018917 *

Also Published As

Publication number Publication date
ATE228829T1 (en) 2002-12-15
AU5171196A (en) 1996-09-18
TW431891B (en) 2001-05-01
EP0821582A2 (en) 1998-02-04
JPH11509169A (en) 1999-08-17
AR003928A1 (en) 1998-09-30
CA2213455A1 (en) 1996-09-06
DE69625189D1 (en) 2003-01-16
EP0821582B1 (en) 2002-12-04
MY113429A (en) 2002-02-28
AU722741B2 (en) 2000-08-10
PA8388101A1 (en) 1997-09-30
WO1996026718A2 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
WO1997048385A3 (en) Controlled release tablet
MY113429A (en) Controlled release tablet containing swellable polyethylene oxide
AU570712B2 (en) Crosslinked, porous polymers for controlled drug delivery
AU6042796A (en) Controlled release formulation having a preformed passageway
CA2200754A1 (en) Process of making dosage units by wet granulation
CA2364845A1 (en) Extending the duration of drug release within the stomach during the fed mode
AU5251896A (en) Controlled release formulation for water soluble drugs in which a passageway is formed in situ
CA2037410A1 (en) Therapeutic compositions with controlled release of medicaments supported on crosslinked polymers and coated with polymer films, and their preparation process
CA2019410A1 (en) Liquid polymer composition, and method of use
DE69803940D1 (en) OPHTHALMIC COMPOSITION WITH EXTENDED RELEASE CONTAINING WATER-SOLUBLE MEDICINAL PRODUCTS
WO1998022097A3 (en) Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
ATE302597T1 (en) STOMACH-RESIDENT ORAL DOSAGE FORMS OF WATER-SOLUBLE DRUGS WITH CONTROLLED RELEASE
EP0213083A3 (en) Controlled release tablet
KR970025607A (en) Sustained Release Nifedipine Formulation
AU7143796A (en) Controlled release matrix for pharmaceuticals
CA2242986A1 (en) Sustained release drug formulations
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
CA2331264A1 (en) Compositions and methods for drug delivery
CA2223588A1 (en) Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
IE900371L (en) Modified release gemfibrozil composition
CA2157323A1 (en) Gepirone dosage form
GEP20033062B (en) Pharmaceutical Composition Comprising Entacapone or Nitecapone and Cross-Linked Cellulose Derivative
PT974355E (en) SOLUBLE VITAMINIC COMPOSITION IN WATER PROVIDING EXCELLENT TABLETS AND PROCESS FOR PRODUCING THE SAME
AU4627096A (en) Pharmaceutical compositions in the form of slow release tablets based on high molecular weight polysaccharide granules
EP0651634A1 (en) CROSSLINKED POLYHYDROXYL MATERIAL FOR ENZYMATICALLY CONTROLLED DRUG RELEASE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2213455

Country of ref document: CA

Ref country code: CA

Ref document number: 2213455

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 526317

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996908487

Country of ref document: EP

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1996908487

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996908487

Country of ref document: EP